arGEN-X, a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies for the treatment of cancer and severe autoimmune diseases, announced today the initiation of a collaboration with
"We are delighted that Bayer, with its long-standing expertise in drug development, will make use of the SIMPLE Antibody(TM) platform. As a company, we are dedicated to forming elite partnerships and feel that with this new collaboration, we have firmly established SIMPLE Antibody(TM) as an innovative solution to reaching intractable targets and tackling unmet needs in antibody discovery," said
With this collaboration, arGEN-X will apply its SIMPLE Antibody(TM) technology to multiple targets submitted by Bayer. The parties will work together to validate human antibody leads in disease-relevant models, with Bayer being responsible for further preclinical and clinical development and commercialization of therapeutic antibody products. Under the terms of the Agreement, Bayer will pay arGEN-X an upfront technology access fee, research support and technical success-based milestones. Bayer will also pay clinical, regulatory and product sales-based milestones as antibody programs progress through clinical development and registration.
"We look forward to collaborating with arGEN-X and exploring the potential of SIMPLE Antibody(TM) technology to complement Bayer's efforts in the discovery and development of first-in-class therapeutic antibodies," said Dr.
arGEN-X is a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies for the treatment of cancer and severe autoimmune diseases. arGEN-X has generated a clinical pipeline of differentiated antibody candidates using its SIMPLE Antibody(TM) discovery platform. SIMPLE Antibody(TM) has a particular strength in addressing novel, complex disease targets that are difficult to access using established antibody technology platforms. Fc engineering technologies - NHance(R), ABDEG(TM) and POTELLIGENT(R) - further enhance the therapeutic properties of SIMPLE Antibody(TM) leads in terms of their residence time in the body, their ability to clear disease targets or pathogenic antibodies and their cell killing potency through Antibody-Dependent Cell-mediated Cytotoxicity (ADCC), respectively. arGEN-X has leveraged its suite of antibody technologies in forging strategic collaborations with pharmaceutical and biotechnology companies to provide new approaches to diseases with unmet medical needs.
For further information, please contact:
Most Popular Stories
- McDonald's Packages Coffee for National Distribution
- Homebuilder Confidence at Highest Since January
- Parents Opt to Keep Baby Photos off Facebook
- HTC Makes Windows Version of Flagship One Phone
- Rising U.S. Consumer Prices Slowed Down in July
- Sprint Cancels Framily, Rolls Out New Data Pricing Plan
- 'Turtles' Easily Tops 'Expendables 3' at Weekend Box Office
- Home Depot Builds Nice Net Income in Q2
- Mike Brown Death Timeline
- St. Francis Names Rodriguez as New Dean